A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
Status:
Completed
Trial end date:
2018-10-26
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label study to assess the PK of single 100 mg oral dose of
enasidenib (CC-90007) in subjects with moderate and severe hepatic impairment, and in matched
healthy control subjects with normal hepatic function.
Degrees of hepatic impairment will be determined during screening by the subject's score
according to Pugh's Modification of Child's Classification of Severity of Liver Disease